The present invention provides a method of producing a reprogrammed cell, said method comprising exposing Stro-1.sup.+ multipotential cells and/or progeny cells thereof to one or more potency-determining factors under conditions sufficient to reprogram the cells. The present invention also provides cells produced by such a method and cells differentiated therefrom in addition to various uses of those cells.

The invention provides a novel anticancer therapeutic having a high effect against solid cancers, lacking the side effects of chemotherapeutics, and being unlikely to cause resistance. Provided is a pharmaceutical composition for cancer treatment prepared by a method having: a stem cell production step for making immortalized stem cells by introducing four types of genes into deciduous tooth dental pulp stem cells obtained from the dental pulp of mammals; and a condition medium preparation step for culturing the immortalized stem cells for a predetermined length of time in serum-free medium at 23-27 C. under conditions of low oxygen concentration at an oxygen concentration of from 0.5% to less than 20%, the pharmaceutical composition containing 1.5 times or more of insulin-like growth factor (IGF-1) and vascular endothelial growth factor (VEGF) than is contained in condition medium prepared when culturing at an oxygen concentration of 20% and otherwise identical conditions.

The present invention provides a method of producing a reprogrammed cell, said method comprising exposing Stro-1.sup.+ multipotential cells and/or progeny cells thereof to one or more potency-determining factors under conditions sufficient to reprogram the cells. The present invention also provides cells produced by such a method and cells differentiated therefrom in addition to various uses of those cells.

The present invention is directed to therapeutic multifunctional immature dental pulp stem cells (IDPSCs), and IDPSCs multi-lineage compositions. The invention is further directed to the use of IDPSCs and compositions to reduce the risk of and/or treat degenerative diseases or for other medicinal and aesthetic purposes.

Disclosed is a use of G007-LK in promoting osteogenic differentiation of dental mesenchymal stem cells and bone tissue regeneration. In vitro experiments of the present application show that G007-LK has the ability to induce SHED to form mineralized nodules and promote osteogenic differentiation; in vivo experiments show that G007-LK pretreatment of SHED for 7 days combined with Geistlich Bio-Oss collagen bone scaffold can enhance the in vivo osteogenic effect of SHED and promote the subcutaneous ectopic osteogenesis of nude mice, indicating that G007-LK has good osteoinductivity and is a potential osteogenic drug. Therefore, G007-LK can promote osteogenic differentiation of dental mesenchymal stem cells and be applied to bone tissue regeneration.

Disclosed is a use of G007-LK in promoting osteogenic differentiation of dental mesenchymal stem cells and bone tissue regeneration. In vitro experiments of the present application show that G007-LK has the ability to induce SHED to form mineralized nodules and promote osteogenic differentiation; in vivo experiments show that G007-LK pretreatment of SHED for 7 days combined with Geistlich Bio-Oss collagen bone scaffold can enhance the in vivo osteogenic effect of SHED and promote the subcutaneous ectopic osteogenesis of nude mice, indicating that G007-LK has good osteoinductivity and is a potential osteogenic drug. Therefore, G007-LK can promote osteogenic differentiation of dental mesenchymal stem cells and be applied to bone tissue regeneration.

Disclosed is a use of G007-LK in promoting osteogenic differentiation of dental mesenchymal stem cells and bone tissue regeneration. In vitro experiments of the present application show that G007-LK has the ability to induce SHED to form mineralized nodules and promote osteogenic differentiation; in vivo experiments show that G007-LK pretreatment of SHED for 7 days combined with Geistlich Bio-Oss collagen bone scaffold can enhance the in vivo osteogenic effect of SHED and promote the subcutaneous ectopic osteogenesis of nude mice, indicating that G007-LK has good osteoinductivity and is a potential osteogenic drug. Therefore, G007-LK can promote osteogenic differentiation of dental mesenchymal stem cells and be applied to bone tissue regeneration.

A medium-based method for inducing specific differentiation of dental stem cells into dopaminergic neurons is provided. The method includes seeding the dental stem cells at a concentration of 5000 cells/cm.sup.2, following 24-hour incubation, introducing the cells into first part neurogenic induction medium and continuing the medium application for 4 days; subsequently, introducing the cells into the second part neurogenic induction medium and continuing the medium application for 2 days; and terminating the differentiation at the end of 6 days. The objective of the present invention is to develop cellular applications for use in treatment of neurodegenerative diseases and medications related to the said diseases.

The present invention includes a functionalized nerve guidance conduit (NGC), methods of making neurotrophic factor-expressing neural crest stem-like cells (NCSC) and/or Schwann cell precursor-like (SCP) cells, methods of making the functionalized nerve guidance conduit, and methods of treating nerve injury using the functionalized nerve guidance conduit.

Methods are described for preparing auditory progenitor cells from gingival mesenchymal cells, for uses such as restoring hearing in hearing impaired individuals.